Measles, mumps, rubella (MMR) vaccine

Indian Journal of Pediatrics

Volumn 70, Issue 7, 2003, Pages 579-584

  Dubey, A P ^a   Banerjee, S ^a  

^a MAULANA AZAD MEDICAL COLLEGE   (India)

Author keywords

Adverse effects; Controversies; Immunization; MMR vaccine

Indexed keywords

GELATIN; LIVE VACCINE; MEASLES MUMPS RUBELLA VACCINE; MEASLES MUMPS VACCINE;

AUTISM; CHILD; CONFERENCE PAPER; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; ENTERITIS; EPIDEMIOLOGICAL DATA; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNIZATION; INDIA; MEASLES; MUMPS; RUBELLA; SEROCONVERSION; SIDE EFFECT; THROMBOCYTOPENIA; VACCINATION; VIRUS MENINGITIS;

EID: 0041734882     PISSN: 00195456     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02723162     Document Type: Conference Paper

References (27)

1. Bhargava I, Chhaparwal BC, Phadke MA, Irani SF, Chhaparwal D, Dhorje S et al. A study of immunogenicity and reactogenicity of indigenously produced MMR vaccine. Indian Pediatr 1995; 32: 983-988.
2. Coughlan S, Connell J, Cohen B, Jin L, Hall WW. Suboptimal measles-mumps-rubella vaccination coverage facilitates an imported measles outbreak in Ireland. Clin Infect Dis 2002; 35: 84-86.
3. Wakefield AJ, Murch SH, Anthony A, Linnell J, Casson DM. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 1998; 351 : 637-641.
4. Yazbak FE. Maternal vaccination with live virus vaccines before, during and after pregnancy predisposes to autism. Presented at: New Challenges in Childhood Immunization Conference of the American Academy of Pediatrics; June 12-13, 2000; Chicago, IL
5. Megson MN. Is autism a G-alpha protein defect reversible with natural vitamin A? Med Hypotheses 2000; 54: 979-983.
6. Taylor B, Miller E, Farrington CP, Petropoulus MC, Favot-Mayaud I, Li J et al. Autism and measles, mumps and rubella vaccine: no epidemiological evidence for a causal association. Lancet 1999; 353: 2026-2029.
7. Kaye JA, Melero-Montes MM, Jick H. Mumps, measles, and rubella vaccine and the incidence of autism recorded by general practitioners: a time trend analysis. BMJ 2001; 322: 460-463.
8. Dales L, Hammer SJ, Smith NJ. Time trends in autism and in MMR immunization coverage in California. JAMA 2001; 285: 1183-1185.
9. Patja A, Davidkin I, Kurki T, Kallio MJ, Valle M, Peltola H et al. Serious adverse events after measles-mumps-rubella vaccination during a fourteen-year prospective follow-up. Pediatr Infect Dis J 2000; 19: 1127-1134.
10. Phelan AT. MMR and autism: an overview of the debate to date. Br J Nurs 2002; 11(9): 621-625.
11. Wakefield AJ, Montgomery SM, Pounder RE. Crohn's disease: the case for measles virus. Ital J Gastroenterol Hepatol 1993; 31: 247-254.
12. Montgomery SM, Morris DL, Pounder RE, Wakefield AJ. Paramyxovirus infections in childhood and subsequent inflammatory bowel disease. Gastroenterology 1999; 116: 796-803.
13. Thompson NP, Montgomery SM, Wadsworth ME, Pounder RE, Wakefield AJ. Early determinants of inflammatory bowel disease: use of two national longitudinal birth cohorts. Eur J Gastroenterol Hepatol 2000; 12: 25-30.
14. Davis RL, Kramarz P, Bohlke K, Destefano F, Chen RT. Measles-mumps-rubella and other measles-containing vaccines do not increase the risk for inflammatory bowel disease: A case-control study from the vaccine safety datalink project. Arch Pediatr Adolesc Med 2001; 155: 354-359.
15. Peltola H, Patja A, Leinikki P, Valle M, Davidkin I, Paunio M. No evidence for measles, mumps, and rubella vaccine-associated inflammatory bowel disease or autism in a 14-year prospective study. Lancet 1998; 351: 1327-1328.
16. Davis RL. Measles vaccination and inflammatory bowel disease: controversy laid to rest? Drug Saf 2001; 24(13): 939-946.
17. Fenichel GM: Neurological complications of immunization. Ann Neurol 1982; 12: 119-128.
18. Sanford R, Kimmel MD. Vaccine adverse events: Separating myth from reality. Am Fam Phy 2002; 66(11): 2113-2120.
19. Makela A, Pekka-Nuorti J, Peltola H. Neurologic disorders after Measles-Mumps-Rubella vaccination. Pediatrics 2002; 110 (5): 957-963.
20. Patja A, Paunio M, Kinnunen E, Junttila O, Hovi T, Peltola H et al. Risk of Guillain-Barre syndrome after measles-mumps-rubella vaccination. J Pediatr 2001; 138(2): 250-254.
21. 2000 American Academy of Pediatrics. Measles, Mumps, Rubella vaccine. In Report of the Committee on Infectious Diseases ("Red Book"), 25th edn. AAP. Elk Grove Village, Illionis, AAP; 2000: 389-395.
22. Crockett RE, Lockey RF. Vaccine hypersensitivity. Imm All Clin North Am 2001; 21(4): 134-164.
23. Pool V, Braun MM, Kelso JM, Mootrey G, Chen RT. Prevalence of Anti-Gelatin IgE Antibodies in People With Anaphylaxis After Measles-Mumps-Rubella Vaccine in the United States. Pediatrics 2002; 110(6): 67-73.
24. CDC. General Recommendations on Immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP). Morb Mortal Wkly Rep 2002; 51(RR-02): 1-35.
25. Dennehy PH, Saracen CI, Peter G. Seroconversion rates to combined measles-mumps-rubella-varicella. Pediatrics 1994; 514-516.
26. Christensen B,Bottinger M. Changes in the immunological patterns against measles, mumps, rubella: A vaccination program studied 3 to 7 years after the introduction of a two dose schedule. Vaccine 1991; 9: 326-329.
27. CDC. Update: International Task Force for Disease Eradication, 1990 and 1991. Morb Mortal Wkly Rep 1992; 41: 40-42.